Enhanced involvement of endothelin in the haemodynamic sequelae of endotoxaemia in conscious, hypertensive, transgenic ((mRen-2)27) rats

British Journal of Pharmacology

Volumn 123, Issue 7, 1998, Pages 1403-1408

  Gardiner, S M ^a   Kemp, P A ^a   March, J E ^a   Bennett, T ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Endothelin; Endotoxaemia; Transgenic rats

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; ENDOTHELIN; LIPOPOLYSACCHARIDE; LOSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR FUNCTION; CONDUCTANCE; CONTROLLED STUDY; ENDOTOXEMIA; HEMODYNAMICS; HINDLIMB; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD VESSEL; MALE; MEAN ARTERIAL PRESSURE; MESENTERY BLOOD VESSEL; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSGENIC ANIMAL; VASODILATATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BLOOD PRESSURE; ENDOTHELINS; ENDOTOXEMIA; HEMODYNAMIC PROCESSES; HYPERTENSION; INDANS; LIPOPOLYSACCHARIDES; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN;

EID: 0031890161     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701762     Document Type: Article

References (30)

1. BENNETT, T., KEMP, P.A., MARCH, J.E. & GARDINER, S.M. (1997). Haemodynamic responses to chronic lipopolysaccharide (LPS) infusion in conscious, hypertensive transgenic ((mRen-2)27) rats: involvement of endothelin. Br. J. Pharmacol., 122, 231P.
2. DOUGLAS, S.A., EDWARDS, R.M., ELLIOTT, J.D. & OHLSTEIN, E.H. (1995a). In vivo pharmacological characterization of the nonpeptide endothelin receptor antagonist SB 209670. Br. J. Pharmacol., 114, 405-413.
3. DOUGLAS, S.A., GELLAI, M., EZEKIEL, M., FEUERSTEIN, G.Z., ELLIOTT, J.D. & OHLSTEIN, E.H. (1995b). Antihypertensive actions of the novel nonpeptide endothelin receptor antagonist SB 209670. Hypertension, 25, 818-822.
4. DOUGLAS, S.A., GELLAI, M., EZEKIEL, M. & OHLSTEIN, E.H. (1994). BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension. J. Hypertens., 12, 561-567.
5. GARDINER, S.M., KEMP, P.A., MARCH, J.E. & BENNETT, T. (1995a). Enhancement of the hypotensive and vasodilator effects of endotoxaemia in conscious rats by the endothelin antagonist, SB 209670. Br. J. Pharmacol., 116, 1718-1719.
6. GARDINER, S.M., KEMP, P.A., MARCH, J.E. & BENNETT, T. (1995b). Cardiac and regional haemodynamics, inducible nitric oxide synthase (NOS) activity, and the effects of NOS inhibitors in conscious, endotoxaemic rats. Br. J. Pharmacol., 116, 2005-2016.
7. GARDINER, S.M., KEMP, P.A., MARCH, J.E. & BENNETT, T. (1996a). Effects of dexamethasone and SB 209670 on the regional haemodynamic responses to lipopolysaccharide in conscious rats. Br. J. Pharmacol., 118, 141-149.
8. GARDINER, S.M., KEMP, P.A., MARCH, J.E. & BENNETT, T. (1996b). Influence of aminoguanidine and the endothelin antagonist, SB 209670, on the regional haemodynamic effects of endotoxaemia in conscious rats. Br. J. Pharmacol., 118, 1822-1828.
9. GARDINER, S.M., KEMP, P.A., MARCH, J.E. & BENNETT, T. (1996c). Temporal differences between the involvement of angiotensin II and endothelin in the cardiovascular responses to endotoxaemia in conscious rats. Br. J. Pharmacol., 119, 1619-1627.
10. GARDINER, S.M., KEMP, P.A., MARCH, J.E. & BENNETT, T. (1996d). Regional haemodynamic effects of antagonists of angiotensin II, endothelin and adrenoceptors in conscious, vasopressin-deficient, genetically hypertensive rats. Br. J. Pharmacol., 118, 325-334.
11. GARDINER, S.M., KEMP, P.A., MARCH, J.E. & BENNETT, T. (1997). Effects of glibenclamide on regional haemodynamic responses to lipopolysaccharide (LPS) in conscious rats. Br. J. Pharmacol., 122, 392P.
12. GARDINER, S.M., MARCH, J.E., KEMP, P.A., MULLINS, J.J. & BENNETT, T. (1995c). Haemodynamic effects of losartan and the endothelin antagonists, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats. Br. J. Pharmacol., 116, 2237-2244.
13. KIOWSKI, W., SUTSCH, G., HUNZIKER, P., MULLER, P., KIM, J., OECHSLIN, E., SCHMITT, R., JONES, R & BERTEL, O. (1995). Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet, 346, 732-736.
14. LEE, M.A., BOHM, M., PAUL, M., BADER, M., GANTEN, U. & GANTEN, D. (1996). Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am. J. Physiol., 270, E919-E929.
15. LOVE, M.P. & MCMURRAY, J.J.V. (1996). Endothelin in chronic heart failure: current position and future prospects. Cardiovasc. Res., 31, 665-674.
16. MARCH, J.E., GARDINER, S.M., KEMP, P.A & BENNETT, T. (1996). Regional haemodynamic responses to vasodilators in conscious, transgenic [(mRen-2)27], hypertensive rats. Br. J. Pharmacol., 117, 227P.
17. MULLINS, J.J., PETERS, J. & GANTEN, D. (1990). Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature, 344, 541-544.
18. 1 receptor gene expression in transgenic (mRen-2) 27 rats. Br. J. Pharmacol., 121, 134-140.
19. NISHIKIBE, M., TSUCHIDA, S., OKADA, M., FUKURODA, T., SHIMAMOTO, K., YANO, M., ISHIKAWA, K. & IKEMOTO, F. (1993). Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci., 52, 717-724.
20. OHLSTEIN, E.H., DOUGLAS, S.A., EZEKIEL, M. & GELLAI, M. (1993). Antihypertensive effects of the endothelin receptor antagonist BQ-123 in conscious spontaneously hypertensive rats. J. Cardiovasc. Pharmacol., 22, (Suppl. 8), S321-S324.
21. OHLSTEIN, E.H., NAMBI, P., DOUGLAS, S.A., EDWARDS, R.M., GELLAJ, M., LAGO, A., LEBER, J.D., COUSINS, R.D., GAO, A., FRAZEE, J.S., PEISHOFF, C.E., BEAN, J.W., EGGLESTON, D.S., ELSHOURBAGY, N.A., KUMAR, C., LEE, J.A., YUE, T.-L., LOUDEN, C., BROOKS, D.P., WEINSTOCK, J., FEUERSTEIN, G., POSTE, G., RUFFOLO, R.R., GLEASON, J.G. & ELLIOTT, J.D. (1994). SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc. Natl. Acad. Sci. U.S.A., 91, 8052-8056.
22. PAPAPETROPOULOS, A., MARCZIN, N., SNEAD, M.D., CHENG, C., MILICI, A. & CATRAVAS, J.D. (1994). Smooth muscle cell responsiveness to nitrovasodilators in hypertensive and normotensive rats. Hypertension, 23, 476-484.
23. PERRETTl, M., DUNCAN, G.S., FLOWER, R.J. & PEERS, S.H. (1993). Serum corticosterone, interleukin-1 and tumour necrosis factor in rat experimental endotoxaemia: comparison between Lewis and Wistar strains. Br. J. Pharmacol., 110, 868-874.
24. SEWER, M.B., KOOP, D.R. & MORGAN, E.T. (1996). Endotoxaemia in rats is associated with induction of the P4504A subfamily and suppression of several other forms of cytochrome P450. Drug Metab. Dispos., 24, 401 -407.
25. SUGIURA, M., INAGAMI, T, & KON, V. (1989). Endotoxin stimulates endothelin release in vivo and in vitro as determined by radioimmunoassay. Biochem. Biophys. Res. Commun., 161, 1220-1227.
26. THEODORSSON-NORHEIM, E. (1987). Friedman and Quade test: BASIC computer program to perform non-parametric two-way analysis of variance and multiple comparisons on ranks of several related samples. Comput. Biol. Med., 17, 85-99.
27. VEMULAPALLI, S., CHIU, P.J.S., RIVELLI, M., FOSTER, C.J. & SYBERTZ, E.J. (1991). Modulation of circulating endothelin levels in hypertension and endotoxaemia in rats. J. Cardiovasc. Pharmacol., 18, 895-903.
28. WALLER, J., GARDINER, S.M., JOSE, J. & BENNETT, T. (1995). Lack of effect of TNF antibodies on the cardiovascular sequelae of lipopolysaccharide infusion in conscious rats. Br. J. Pharmacol., 116, 2487-2495.
29. WU, C.-C., HONG, H.-J., CHOU, T.-C., DING, Y.-A. & YEN, M.-S. (1996). Evidence for inducible nitric oxide synthase in spontaneously hypertensive rats. Biochem. Biophys. Res. Commun., 228, 459-466.
30. YEN, M.-H., LIU, Y.-C., HONG, H.-J., SHEU, J.-R. & WU, C.-C. (1997). Role of nitric oxide in lipopolysaccharide-induced mortality from spontaneously hypertensive rats. Life Sci., 60, 1223-1230.